Loading...
Beijing Tong Ren Tang Chinese Medicine Company Limited
3613.HK•HKSE
Healthcare
Medical - Pharmaceuticals
HK$8.84
HK$-0.05(-0.56%)
Beijing Tong Ren Tang Chinese Medicine Company Limited (3613.HK) Financial Performance & Statements
Review Beijing Tong Ren Tang Chinese Medicine Company Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
5.69%
↑ 5.69%
Operating Income Growth
-7.57%
↓ 7.57%
Net Income Growth
-7.42%
↓ 7.42%
Operating Cash Flow Growth
-100.00%
↓ 100.00%
Operating Margin
35.80%
↑ 35.80%
Gross Margin
66.10%
↑ 66.10%
Net Profit Margin
31.04%
↑ 31.04%
ROE
12.70%
↑ 12.70%
ROIC
13.34%
↑ 13.34%
Beijing Tong Ren Tang Chinese Medicine Company Limited (3613.HK) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Beijing Tong Ren Tang Chinese Medicine Company Limited stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $473.56M | $473.56M | $332.26M | $332.26M |
| Cost of Revenue | $166.78M | $166.78M | $106.37M | $106.37M |
| Gross Profit | $306.78M | $306.78M | $225.88M | $225.88M |
| Gross Profit Ratio | $0.65 | $0.65 | $0.68 | $0.68 |
| R&D Expenses | $4.56M | $4.56M | $0.00 | $0.00 |
| SG&A Expenses | $148.58M | $148.58M | $98.40M | $98.40M |
| Operating Expenses | $147.76M | $147.76M | $96.45M | $96.45M |
| Total Costs & Expenses | $314.54M | $314.54M | $202.82M | $202.82M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.17M | $4.65M | $4.65M | $4.65M |
| EBITDA | $161.76M | $162.24M | $134.09M | $134.09M |
| EBITDA Ratio | $0.34 | $0.34 | $0.40 | $0.40 |
| Operating Income | $159.02M | $159.02M | $129.44M | $129.44M |
| Operating Income Ratio | $0.34 | $0.34 | $0.39 | $0.39 |
| Other Income/Expenses (Net) | $14.04M | $14.04M | $12.38M | $12.38M |
| Income Before Tax | $173.07M | $173.07M | $141.82M | $141.82M |
| Income Before Tax Ratio | $0.37 | $0.37 | $0.43 | $0.43 |
| Income Tax Expense | $28.65M | $28.65M | $21.65M | $21.65M |
| Net Income | $140.25M | $140.25M | $109.89M | $109.89M |
| Net Income Ratio | $0.30 | $0.30 | $0.33 | $0.33 |
| EPS | $0.17 | $0.17 | $0.13 | $0.13 |
| Diluted EPS | $0.17 | $0.17 | $0.13 | $0.13 |
| Weighted Avg Shares Outstanding | $837.10M | $837.10M | $837.11M | $837.11M |
| Weighted Avg Shares Outstanding (Diluted) | $837.10M | $837.10M | $837.10M | $837.10M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan